Difference between revisions of "Neuromod Tools"
(Created page with 'Lenire is a bimodal neuromodulation tool which works by delivering mild electric pulses to the tongue, through an intra-oral component called the 'Tonguetip ®', integrated wi...') |
m |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | Panakès Allies is a Financial backing company, based in Milan, which invests in one of the most enthusiastic business and groups, creating revolutionary technologies and items, in the field of life sciences, [https://www.protopage.com/odwaceojwe Bookmarks] intending to improve the lives of people worldwide.<br><br>Founded in 2010 by Dr. Ross 'Neill, CHIEF EXECUTIVE OFFICER, Neuromod Devices is a medical technology company that specialises in the layout and advancement of neuromodulation technologies to deal with the professional demands of underserved client populaces who cope with chronic and debilitating conditions.<br><br>Since the previous round of funding increased in October 2020, the company has actually made progression commercialising Lenire, broadening the device's accessibility throughout Europe, establishing a completely possessed US subsidiary, Neuromod United States Inc, and safeguarding US market approval from the FDA. <br><br>The very first of these trials, TENT-A1, represents among the biggest and longest followed-up professional trials ever performed in the ringing in the ears field and was the cover story for the scientific journal Science Translational Medicine in October 2020. | |
Latest revision as of 19:41, 15 June 2024
Panakès Allies is a Financial backing company, based in Milan, which invests in one of the most enthusiastic business and groups, creating revolutionary technologies and items, in the field of life sciences, Bookmarks intending to improve the lives of people worldwide.
Founded in 2010 by Dr. Ross 'Neill, CHIEF EXECUTIVE OFFICER, Neuromod Devices is a medical technology company that specialises in the layout and advancement of neuromodulation technologies to deal with the professional demands of underserved client populaces who cope with chronic and debilitating conditions.
Since the previous round of funding increased in October 2020, the company has actually made progression commercialising Lenire, broadening the device's accessibility throughout Europe, establishing a completely possessed US subsidiary, Neuromod United States Inc, and safeguarding US market approval from the FDA.
The very first of these trials, TENT-A1, represents among the biggest and longest followed-up professional trials ever performed in the ringing in the ears field and was the cover story for the scientific journal Science Translational Medicine in October 2020.